PRKAR2A antibody
Principal name
PRKAR2A antibody
Alternative names for PRKAR2A antibody
PRKAR2, PKR2, protein kinase A RII-alpha, PKA RII, PKA R2, cAMP-dependent protein kinase type II-alpha regulatory subunit
SwissProt ID
O49196 (Arath), P00515 (Bovin), P05207 (Pig), P12367 (Mouse), P12368 (Rat), P13861 (Human)
Ncbi ID
NP_001178296, 9606, NP_004148.1, NM_004157, NP_004148, NM_019264
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Immunocytochemistry/Immunofluorescence (ICC/IF), Functional assay (FN), Western blot / Immunoblot (WB), Paraffin Sections (P), ELISA (detection) (E(detection)), Flow Cytometry (F)
Background of PRKAR2A antibody
The second messenger cyclic AMP (cAMP) mediates diverse cellular responses to external signals such as proliferation, ion transport, regulation of metabolism and gene transcription by activation of the cAMP-dependent protein kinase (cAPK or PKA). Activation of PKA occurs when cAMP binds to the two regulatory subunits of the tetrameric PKA holoenzyme resulting in release of active catalytic subunits. Three catalytic (C) subunits have been identified, designated Cα, Cβ and Cγ, that each represent specific gene products. Cα and Cβ are closely related (93% amino acid sequence similarity), where as Cγ displays 83% and 79% similarity to Cα and Cβ, respectively. Activation of transcription upon elevation of cAMP levels results from translocation of PKA to the nucleus where it phosphorylates the transcription factor cAMP response element binding protein (CREB) on serine 133 which in turn leads to TFIIB binding to TATA-box-binding protein TBP1, thus linking phospho-CREB to the pol II transcription initiation complex.
General readings
Yang H., et al. (2013) J. Biol. Chem. 288 (12), 8737-8749
Immunoperoxidase of monoclonal antibody to PRKAR2A on formalin-fixed paraffin-embedded human salivary gland. [antibody concentration 3 ug/ml]
Immunofluorescence of monoclonal antibody to PRKAR2A on HeLa cell . [antibody concentration 10 ug/ml]
PRKAR2A monoclonal antibody (M01), clone 6A9 Western Blot analysis of PRKAR2A expression in HeLa ( Cat # L013V1 ).
Detection limit for recombinant GST tagged PRKAR2A is approximately 0.03ng/ml as a capture antibody.
Western blot (WB) analysis of PKA IIα reg antibody (Cat.-No.: AP06667PU-N) in extracts from 293 cells.
Western blot analysis of PRKAR2A polyclonal antibody ( Cat # PAB4582 ) in mouse brain tissue lysate . PRKAR2A ( arrow ) was detected using purified PRKAR2A polyclonal antibody ( Cat # PAB4582 ) . Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence .
PRKAR2A MaxPab polyclonal antibody. Western Blot analysis of PRKAR2A expression in human colon.
Western Blot analysis of PRKAR2A expression in transfected 293T cell line (H00005576-T01) by PRKAR2A MaxPab polyclonal antibody.Lane1:PRKAR2A transfected lysate(42.02 KDa).Lane2:Non-transfected lysate.
Human Fetal Kidney; WB Suggested Anti-PRKAR2A Antibody. . Titration: 1.0 ug/ml. . Positive Control: Fetal Kidney; PRKAR2A antibody - middle region (ARP61563_P050) in Human Fetal Kidney cells using Western Blot
Immunohistochemical staining of paraffin-embedded prostate tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501104, Dilution 1:50)
Anti-PRKAR2A mouse monoclonal antibody (TA501104) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY PRKAR2A(RC220376).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PRKAR2A (RC220376, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-PRKAR2A.
HEK293T cells transfected with either RC220376 overexpress plasmid(Red) or empty vector control plasmid(Blue) were immunostained by anti-PRKAR2A antibody(TA501104), and then analyzed by flow cytometry.
Immunohistochemical staining of paraffin-embedded Carcinoma of prostate tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501106, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of ovary tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501106, Dilution 1:50)
Anti-PRKAR2A mouse monoclonal antibody (TA501106) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY PRKAR2A(RC220376).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PRKAR2A (RC220376, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-PRKAR2A.
HEK293T cells transfected with either RC220376 overexpress plasmid(Red) or empty vector control plasmid(Blue) were immunostained by anti-PRKAR2A antibody(TA501106), and then analyzed by flow cytometry.
Immunohistochemical staining of paraffin-embedded pancreas tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501129, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Kidney tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501129, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Carcinoma of liver tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501129, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of colon tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501129, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded prostate tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501129, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of ovary tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501129, Dilution 1:50)
Anti-PRKAR2A mouse monoclonal antibody (TA501129) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY PRKAR2A(RC220376).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PRKAR2A (RC220376, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-PRKAR2A.
Flow cytometric Analysis of Jurkat cells, using anti-PRKAR2A antibody(TA501129),(Red), compared to a nonspecific negative control antibody,(Blue).
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of ovary tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501143, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of colon tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501143, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Carcinoma of liver tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501143, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Kidney tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501143, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded pancreas tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501143, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded prostate tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501143, Dilution 1:50)
Anti-PRKAR2A mouse monoclonal antibody (TA501143) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY PRKAR2A(RC220376).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PRKAR2A (RC220376, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-PRKAR2A.
HEK293T cells transfected with either RC220376 overexpress plasmid(Red) or empty vector control plasmid(Blue) were immunostained by anti-PRKAR2A antibody(TA501143), and then analyzed by flow cytometry.
Immunohistochemical staining of paraffin-embedded Kidney tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501144, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded breast tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501144, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of colon tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501144, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Carcinoma of liver tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501144, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded liver tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501144, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded prostate tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501144, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of ovary tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501144, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded pancreas tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501144, Dilution 1:50)
Anti-PRKAR2A mouse monoclonal antibody (TA501144) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY PRKAR2A(RC220376).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PRKAR2A (RC220376, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-PRKAR2A.
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of colon tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501145, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded liver tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501145, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Kidney tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501145, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of ovary tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501145, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded prostate tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501145, Dilution 1:50)
Anti-PRKAR2A mouse monoclonal antibody (TA501145) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY PRKAR2A(RC220376).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PRKAR2A (RC220376, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-PRKAR2A.
HEK293T cells transfected with either RC220376 overexpress plasmid(Red) or empty vector control plasmid(Blue) were immunostained by anti-PRKAR2A antibody(TA501145), and then analyzed by flow cytometry.
Immunohistochemical staining of paraffin-embedded Carcinoma of Human prostate tissue using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501146)
Immunohistochemical staining of paraffin-embedded Human prostate tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501146)
Immunohistochemical staining of paraffin-embedded Human Kidney tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501146)
Anti-PRKAR2A mouse monoclonal antibody (TA501146) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY PRKAR2A(RC220376).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PRKAR2A (RC220376, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-PRKAR2A.
Western blot analysis of extracts (35ug) from 9 different cell lines by using anti-PRKAR2A monoclonal antibody at 1:200 dilution. (HepG2: human; HeLa: human; SVT2: mouse; A549: human; COS7: monkey; Jurkat: human; MDCK: canine; PC12: rat; MCF7: human)
HEK293T cells transfected with either RC220376 overexpress plasmid(Red) or empty vector control plasmid(Blue) were immunostained by anti-PRKAR2A antibody(TA501146), and then analyzed by flow cytometry.
Flow cytometric Analysis of Jurkat cells, using anti-PRKAR2A antibody(TA501146),(Red), compared to a nonspecific negative control antibody(TA50011),(Blue).
Flow cytometric Analysis of Hela cells, using anti-PRKAR2A antibody(TA501146),(Red), compared to a nonspecific negative control antibody(TA50011),(Blue).
Immunohistochemical staining of paraffin-embedded Human prostate tissue within the normal limits using anti-PRKAR2A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA501195, Dilution 1:50)
Anti-PRKAR2A mouse monoclonal antibody (TA501195) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY PRKAR2A(RC220376 ).
Western blot analysis of extracts (35ug) from 9 different cell lines by using anti-PRKAR2A monoclonal antibody.
Western blot analysis of extracts (10ug) from 10 Human tissue by using anti-PRKAR2A monoclonal antibody at 1:500 (1: Testis; 2: Omentum; 3: Uterus; 4: Breast; 5: Brain; 6: Liver; 7: Ovary; 8: Thyroid gland; 9: colon;10: spleen).
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PRKAR2A (RC220376, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-PRKAR2A.
HEK293T cells transfected with either RC220376 overexpress plasmid(Red) or empty vector control plasmid(Blue) were immunostained by anti-PRKAR2A antibody(TA501195), and then analyzed by flow cytometry.
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| AP06667PU-N | PRKAR2A antibody |
||||||
 |
Rabbit | Aff - Purified | Hu | ICC/IF, P, WB |
0.1 mg /
€370.00
|
||
| OriGene Technologies GmbH | |||||||